What is adalimumab? What conditions is adalimumab suitable for?
Adalimumab (Humira) is a self-injectable biotherapeutic drug. It has been approved by the State Food and Drug Administration (CFDA) for two indications, namely rheumatoid arthritis and ankylosing spine. inflammation.
In 2013, through the study of adverse events in clinical trials of adalimumab for various indications in the past 12 years, no new adverse reaction safety signals beyond previous experience were found. In adalimumab-treated patients, the overall malignancy incidence was as expected in the general population. This drug is usually used alone or in combination with methotrexate.
Adalimumab has been approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, and Crohn's disease in the United States and the European Union. To a large extent relieve the patient's symptoms. The launch of adalimumab in China brings a new dawn to the treatment of rheumatoid arthritis patients in China and opens a new era of rheumatoid immune disease treatment.
Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by symmetry, multiple joints, and small joints. It is known as "immortal cancer". The immune system of the patient will destroy healthy joints and cause joint damage. Pain, swelling, stiffness, symptoms of fatigue and weakness, late stiffness and deformity, severely impaired function, and ultimately loss of joint function.
Humira in combination with methotrexate for the treatment of Adult patients with moderately to severely active rheumatoid arthritis who have not responded well to disease-modifying antirheumatic drugs (DMARDs), including methotrexate. The combination of Humira and methotrexate slowed the progression of joint damage (shown on X-rays) and improved physical function. Compared with traditional drugs, these drugs have strong and long-lasting efficacy, can effectively relieve disease symptoms, imaging progress, and functional level, and have good safety, and are suitable for various rheumatoid arthritis patients.
Ankylosing spondylitis
Ankylosing spondylitis (AS) is a disease characterized by inflammation of the sacroiliac joints and spinal attachment points. Strong association with HLA-B27. Certain microorganisms, such as Klebsiella, share antigens with susceptible individuals' own tissues, which can trigger abnormal immune responses. Ankylosing spondylitis is a chronic inflammatory disease characterized by fibrosis and ossification of the large joints of the limbs, as well as the annulus fibrosus of the intervertebral disc and its adjacent connective tissue, as well as joint stiffness.
Humira is used in adult patients with severe active ankylosing spondylitis who have not responded well to conventional therapy. It has the characteristics of fast onset and good curative effect. The condition of most patients can be rapidly and significantly improved, such as morning stiffness, low back pain, peripheral arthritis, tendonitis, chest expansion, ESR and CRP, etc. After a period of application, the patient's physical function and health-related quality of life Significant improvement, in particular, can restore some newly emerged spinal mobility dysfunction.
Minbiotech is a adalimumabb manufacturer and adalimumabb factory, Minbiotech CAS:331731-18-1, adalimumabb supplier, Welcome to visit our website.
Related news of Minbiotech bio-pharmacy
Maytansinol properties, uses and production process Maytansinol is the common pa
Specific contraindications for the use of Simorox tablets
